The document contains an internal factor evaluation (IFE) matrix for Pfizer, Inc. that lists key internal strengths and weaknesses and assigns them weights and ratings. It also contains an external factor evaluation (EFE) matrix that lists key external opportunities and threats and assigns them weights and ratings. However, the matrices are incomplete as they do not contain weighted scores. The document also includes a comparison matrix measuring the performance of Pfizer, Merck and Novartis based on various key success factors and their respective weighted scores.
The document contains an internal factor evaluation (IFE) matrix for Pfizer, Inc. that lists key internal strengths and weaknesses and assigns them weights and ratings. It also contains an external factor evaluation (EFE) matrix that lists key external opportunities and threats and assigns them weights and ratings. However, the matrices are incomplete as they do not contain weighted scores. The document also includes a comparison matrix measuring the performance of Pfizer, Merck and Novartis based on various key success factors and their respective weighted scores.
The document contains an internal factor evaluation (IFE) matrix for Pfizer, Inc. that lists key internal strengths and weaknesses and assigns them weights and ratings. It also contains an external factor evaluation (EFE) matrix that lists key external opportunities and threats and assigns them weights and ratings. However, the matrices are incomplete as they do not contain weighted scores. The document also includes a comparison matrix measuring the performance of Pfizer, Merck and Novartis based on various key success factors and their respective weighted scores.
The document contains an internal factor evaluation (IFE) matrix for Pfizer, Inc. that lists key internal strengths and weaknesses and assigns them weights and ratings. It also contains an external factor evaluation (EFE) matrix that lists key external opportunities and threats and assigns them weights and ratings. However, the matrices are incomplete as they do not contain weighted scores. The document also includes a comparison matrix measuring the performance of Pfizer, Merck and Novartis based on various key success factors and their respective weighted scores.
- - - - - - - - - tion Matrix (EFE) For PFIZER, Inc.
Rating Weighted Score - - - - - - -
- - - - - - - 1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7
1 2 3 4 5
1 2 3 4 5 6 7 Strength Well-known for its prescription medicine and for its OTC medical products. Operates in three business segments - Pharmaceuticals, animal health, Corporate & others Partnership with Eisai allowede Pfizer the distribution of the world's leading medicine Double digit growth in the international sales Pfizer invested more in R&D as shown in its increasing R&D expenditures There was a reduction in the SG&A Expenses Pfizer is the leading pharmaceutical company with 47.32Billion revenues Pfizer has around 80,250 employees Established goodwill through partnership with world-class foundations and nonprofit organizations Leading biopharmaceutical company in emerging markets through bold and innovative partnerships. With low-cost publicity in the way of drug give aways.
Weaknesses Double-digit decline in the US sales Pfizers net income for the past three years has a declining trend Pfizer has the lowest earnings per share of $1.23 Pfizer is currently facing litigation in several courts around the world. Assets is declining while liabilities are increasing Bismirched reputation due to liability on certain drugs due to unethical practices of its representatives. Tough competition from other major pharmaceutical brands (limits the market share)
Opportunities Acquisition of Wyeth will lead to diversification of products offered and expansion of presence internationally Sale of prescription drugs in emerging markets is increasing. Improved Research and Development acquired from Wyeth. Global penetration through mergers and acquisitions Increasing awareness about healthcare needs
Threats Eisai threatened to terminate its partnership with Pfizer if the latter acquires Wyeth. Pfizer is subject to unexpected changes in revenues and profits as a resulf of unpredictable currency fluctuations. Pfizer is regulated in multiple and diverse regulatory environments. Pfizer faces high competition in all its business segments Acquisition of Wyeth will also increase Pfizer's debt which is risky for Pfizer's decreasing revenues Acquisition of Wyeth will also increase Pfizer's burden on pending lawsuits and litigation as it will shoulder Wyeth's lawsuits. Sale of prescriptive drugs in the US is decreasing year on year CPM Pfizer Merck Novartis Key Success Factors Weight Rating Weighted Score Rating Weighted Score Rating Market Cap 0.15 4 0.6 3 1.8 4 Employees 0.1 3 0.3 2 0.6 4 Revenue 0.15 4 0.6 3 1.8 4 Gross Margin 0.15 4 0.6 3 1.8 2 Operating Margin 0.15 4 0.6 3 1.8 3 Net Income 0.15 4 0.6 3 1.8 4 EPS 0.15 2 0.3 3 0.9 4 1 Novartis Weighted Score 7.2 2.4 7.2 3.6 5.4 7.2 3.6
